Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272509 | 0.88 | KMT2A (0.57) | SMN1; SMN2POLBKMT2AHTTLMNA | |
| SCHEMBL21498994 | 0.86 | KMT2A (0.59) | SMN1; SMN2POLBKMT2AHTTLMNA | |
| SCHEMBL22237406 | 0.86 | KDM4E (0.62) | SMN1; SMN2POLBKMT2ALMNAMEN1 | |
| SCHEMBL10223990 | 0.84 | KMT2A (0.56) | SMN1; SMN2POLBKMT2AHTTLMNA | |
| SCHEMBL10272937 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBKMT2ALMNAMEN1 | |
| SCHEMBL8171451 | 0.84 | KMT2A (0.56) | SMN1; SMN2POLBKMT2AHTTLMNA | |
| SCHEMBL21103331 | 0.83 | KMT2A (0.53) | SMN1; SMN2POLBKMT2AHTTLMNA | |
| SCHEMBL10174538 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBKMT2ALMNAMEN1 | |
| SCHEMBL9122812 | 0.82 | LMNA (0.55) | SMN1; SMN2POLBKMT2ALMNAMEN1 | |
| SCHEMBL765937 | 0.82 | PPARA (0.68) | SMN1; SMN2POLBKMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954217-B2 | Sigma receptor binders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | UNIV TEXAS (US) | 2020-04-16 | — | — | US | disclosed |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
| WO-2019154366-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏奥赛康药业有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20190177301-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-06-13 | — | — | US | disclosed |
| WO-2017190109-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017190107-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | SMN1; SMN2 4547/4885POLB 1491/4885KMT2A 4058/4885 |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | SMN1; SMN2 4561/4885POLB 3849/4885KMT2A 1671/4885 |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | SMN1; SMN2 4283/4885POLB 4871/4885KMT2A 1854/4885 |
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SMN1; SMN2 102/4885POLB 2810/4885KMT2A 812/4885 |
| US-10954217-B2 | Sigma receptor binders | SIGMAR1, OPRK1, OPRL1 | SMN1; SMN2 512/4885POLB 1032/4885KMT2A 2607/4885 |
| US-20190177301-A1 | SIGMA RECEPTOR BINDERS | SIGMAR1, OPRK1, OPRL1 | SMN1; SMN2 512/4885POLB 1032/4885KMT2A 2607/4885 |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SMN1; SMN2 102/4885POLB 2810/4885KMT2A 812/4885 |
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | ELAVL1, ADH1A, NGF | SMN1; SMN2 102/4885POLB 2810/4885KMT2A 812/4885 |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | SMN1; SMN2 4283/4885POLB 4871/4885KMT2A 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.